These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 16525200)

  • 1. Anti-angiogenesis therapy in pancreatic carcinoma.
    Saif MW
    JOP; 2006 Mar; 7(2):163-73. PubMed ID: 16525200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic cancer: from molecular signature to target therapy.
    Longo R; Cacciamani F; Naso G; Gasparini G
    Crit Rev Oncol Hematol; 2008 Dec; 68(3):197-211. PubMed ID: 18436450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts.
    Holloway SE; Beck AW; Shivakumar L; Shih J; Fleming JB; Brekken RA
    Ann Surg Oncol; 2006 Aug; 13(8):1145-55. PubMed ID: 16791450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer.
    Yuan P; Wang L; Wei D; Zhang J; Jia Z; Li Q; Le X; Wang H; Yao J; Xie K
    Cancer; 2007 Dec; 110(12):2682-90. PubMed ID: 17973266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-angiogenic therapy against gastrointestinal tract cancers.
    Iwasaki J; Nihira S
    Jpn J Clin Oncol; 2009 Sep; 39(9):543-51. PubMed ID: 19531544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Recent studies on anti-angiogenesis in cancer therapy].
    Kishi K; Milas L; Hunter N; Sato M
    Nihon Rinsho; 2000 Aug; 58(8):1747-62. PubMed ID: 10944947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy.
    Greenberg JI; Cheresh DA
    Expert Opin Biol Ther; 2009 Nov; 9(11):1347-56. PubMed ID: 19761418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer.
    Ischenko I; Guba M; Yezhelyev M; Papyan A; Schmid G; Green T; Fennell M; Jauch KW; Bruns CJ
    Angiogenesis; 2007; 10(3):167-82. PubMed ID: 17486419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The present and future of angiogenesis-directed treatments of colorectal cancer.
    O'Dwyer PJ
    Oncologist; 2006 Oct; 11(9):992-8. PubMed ID: 17030640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-angiogenic strategies for cancer therapy (Review).
    Benouchan M; Colombo BM
    Int J Oncol; 2005 Aug; 27(2):563-71. PubMed ID: 16010440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia and angiogenesis in pancreatic cancer.
    Garcea G; Doucas H; Steward WP; Dennison AR; Berry DP
    ANZ J Surg; 2006 Sep; 76(9):830-42. PubMed ID: 16922908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting angiogenesis in head and neck cancer.
    Seiwert TY; Cohen EE
    Semin Oncol; 2008 Jun; 35(3):274-85. PubMed ID: 18544442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The importance of angiogenesis in pancreatic cancer].
    Myśliwiec P; Dadan J
    Przegl Lek; 2009; 66(3):155-8. PubMed ID: 19689042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow-derived proangiogenic cells in pancreatic cancer.
    Mizukami Y
    J Gastroenterol Hepatol; 2012 Mar; 27 Suppl 2():23-6. PubMed ID: 22320912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor growth suppression in pancreatic cancer by a putative metastasis suppressor gene Cap43/NDRG1/Drg-1 through modulation of angiogenesis.
    Maruyama Y; Ono M; Kawahara A; Yokoyama T; Basaki Y; Kage M; Aoyagi S; Kinoshita H; Kuwano M
    Cancer Res; 2006 Jun; 66(12):6233-42. PubMed ID: 16778198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors.
    Idbaih A; Ducray F; Sierra Del Rio M; Hoang-Xuan K; Delattre JY
    Oncologist; 2008 Sep; 13(9):978-92. PubMed ID: 18779539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
    Shojaei F; Ferrara N
    Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting angiogenesis for the treatment of sarcoma.
    Balasubramanian L; Evens AM
    Curr Opin Oncol; 2006 Jul; 18(4):354-9. PubMed ID: 16721130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endogenous angiogenesis inhibitors.
    Folkman J
    APMIS; 2004; 112(7-8):496-507. PubMed ID: 15563312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New antiangiogenetic agents and non-small cell lung cancer.
    Gridelli C; Rossi A; Maione P
    Crit Rev Oncol Hematol; 2006 Oct; 60(1):76-86. PubMed ID: 16843002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.